Probstfield J, Wright JT Jr, Alderman MH, Weiss RJ, Piller L, Bet-
tencourt J, Walsh SM; ALLHAT Collaborative Research Group. Success
and predictors of blood pressure control in diverse North American
settings: the antihypertensive and lipid-lowering treatment to prevent
heart attack trial (ALLHAT). J Clin Hypertens (Greenwich). 2002;4:
393– 404.
3. Black HR, Elliott WJ, Grandits G, Grambsch P, Lucente T, White WB,
Neaton JD, Grimm RH Jr, Hansson L, Lacourciere Y, Muller J, Sleight P,
Weber MA, Williams G, Wittes J, Zanchetti A, Anders RJ; CONVINCE
Research Group. Principal results of the Controlled Onset Verapamil
Investigation of Cardiovascular End Points (CONVINCE) trial. JAMA.
2003;289:2073–2082.
4. Hansson L, Zanchetti A, Carruthers SG, Dahlo¨f B, Elmfeldt D, Julius S,
Me´nard J, Rahn KH, Wedel H, Westerling S. Effects of intensive blood-
pressure lowering and low-dose aspirin in patients with hypertension:
principal results of the Hypertension Optimal Treatment (HOT) ran-
domised trial. HOT Study Group. Lancet. 1998;351:1755–1762.
5. Batterink J, Stabler SN, Tejani AM, Fowkes CT. Spironolactone for
hypertension. Cochrane Database Syst Rev. 2010;8:CD008169.
6. Ghose RP, Hall PM, Bravo EL. Medical management of aldosterone-
producing adenomas. Ann Intern Med. 1999;131:105–108.
7. Lim PO, Jung RT, MacDonald TM. Raised aldosterone to renin ratio
predicts antihypertensive efficacy of spironolactone: a prospective cohort
follow-up study. Br J Clin Pharmacol. 1999;48:756 –760.
8. Nishizaka MK, Zaman MA, Calhoun DA. Efficacy of low-dose spirono-
lactone in subjects with resistant hypertension. Am J Hypertens. 2003;
16:925–930.
9. Ouzan J, Pe´rault C, Lincoff AM, Carre´ E, Mertes M. The role of spi-
ronolactone in the treatment of patients with refractory hypertension.
Am J Hypertens. 2002;15:333–339.
10. Sharabi Y, Adler E, Shamis A, Nussinovitch N, Markovitz A, Grossman
E. Efficacy of add-on aldosterone receptor blocker in uncontrolled hyper-
tension. Am J Hypertens. 2006;19:750 –755.
11. Lane DA, Shah S, Beevers DG. Low-dose spironolactone in the man-
agement of resistant hypertension: a surveillance study. J Hypertens.
2007;25:891– 894.
12. Chapman N, Dobson J, Wilson S, Dahlo¨f B, Sever PS, Wedel H, Poulter
NR; Anglo-Scandinavian Cardiac Outcomes Trial Investigators. Effect of
spironolactone on blood pressure in subjects with resistant hypertension.
Hypertension. 2007;49:839 – 845.
13. Jansen PM, Danser AH, Imholz BP, van den Meiracker AH. Aldoste-
rone-receptor antagonism in hypertension. J Hypertens. 2009;27:
680 – 691.
14. Vaclavik J, Sedlak R, Plachy M, Navratil K, Plasek J, Husar R,
Kocianova E, Taborsky M. Addition of spironolactone in patients with
resistant arterial hypertension (ASPIRANT) – study protocol. Biomed
Pap Med Fac Univ Palacky Olomouc Czech Repub. 2011;155: E-pub
ahead of print. DOI: 10.5507/bp.155.2011.004.
15. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more
accurate method to estimate glomerular filtration rate from serum creat-
inine: a new prediction equation. Modification of Diet in Renal Disease
Study Group. Ann Intern Med. 1999;130:461– 470.
16. O’Brien E, Waeber B, Parati G, Staessen J, Myers MG, on behalf of the
European Society of Hypertension Working Group on Blood Pressure
Monitoring. Blood pressure measuring devices: recommendations of the
European Society of Hypertension. Br Med J. 2001;322:531–536.
17. Association for the Advancement of Medical Instrumentation. American
National Standard. Electronic or Automated Sphygmomanometers.
Arlington, VA: AAMI; 1993.
18. O’Brien E, Asmar R, Beilin L, Imai Y, Mancia G, Mengden T, Myers M,
Padfield P, Palatini P, Parati G, Pickering T, Redon J, Staessen J, Stergiou
G, Verdecchia P. European Society of Hypertension Working Group on
Blood Pressure Monitoring. Practice guidelines of the European Society
of Hypertension for clinic, ambulatory and self blood pressure mea-
surement. J Hypertens. 2005;23:697–701.
19. Funder JW, Carey RM, Fardella C, Gomez-Sanchez CE, Mantero F,
Stowasser M, Young WF Jr, Montori VM; Endocrine Society. Case
detection, diagnosis, and treatment of patients with primary aldoste-
ronism: an endocrine society clinical practice guideline. J Clin Endo-
crinol Metab. 2008;93:3266 –3281.
20. Zannad F. Aldosterone antagonist therapy in resistant hypertension.
J Hypertens. 2007;25:747–750.
21. Saha C, Eckert GJ, Ambrosius WT, Chun TY, Wagner MA, Zhao Q, Pratt
JH. Improvement in blood pressure with inhibition of the epithelial
sodium channel in blacks with hypertension. Hypertension. 2005;46:
481– 487.
22. Alvarez-Alvarez B, Abad-Cardiel M, Fernandez-Cruz A, Martell-Claros
N. Management of resistant arterial hypertension: role of spironolactone
versus double blockade of the renin-angiotensin-aldosterone system.
J Hypertens. 2010;28:2329 –2335.
23. London GM. Role of arterial wall properties in the pathogenesis of
systolic hypertension. Am J Hypertens. 2005;18:19S–22S.
24. Mahmud A, Feely J. Aldosterone-to-renin ratio, arterial stiffness, and the
response to aldosterone antagonism in essential hypertension. Am J
Hypertens. 2005;18:50 –55.
25. Benetos A, Rudnichi A, Safar M, Guize L. Pulse pressure and cardiovas-
cular mortality in normotensive and hypertensive subjects. Hypertension.
1998;32:560 –564.
26. Franklin SS, Khan SA, Wong ND, Larson MG, Levy D. Is pulse pressure
useful in predicting risk for coronary heart disease? The Framingham
Heart Study. Circulation. 1999;100:354 –360.
27. Blacher J, Staessen JA, Girerd X, Gasowski J, Thijs L, Liu L, Wang JG,
Fagard RH, Safar ME. Pulse pressure not mean pressure determines
cardiovascular risk in older hypertensive patients. Arch Intern Med.
2000;160:1085–1089.
28. Kert MJ, Tarr LW, Franklin S, Gold E, Okun R, Maxwell M. Experience
with the use of an aldosterone antagonist in selected hypertensive
patients. Angiology. 1972;23:617– 627.
29. Khosla N, Kalaitzidis R, Bakris GL. Predictors of hyperkalemia risk
following hypertension control with aldosterone blockade. Am J Nephrol.
2009;30:418 – 424.
30. de Souza F, Muxfeldt E, Fiszman R, Salles G. Efficacy of spironolactone
therapy in patients with true resistant hypertension. Hypertension. 2010;
55:147–152.
31. Parthasarathy HK, Alhashmi K, McMahon AD, Struthers AD, McInnes
GT, Ford I, Connell JM, MacDonald TM. Does the ratio of serum
aldosterone to plasma renin activity predict the efficacy of diuretics in
hypertension? Results of RENALDO. J Hypertens. 2010;28:170 –177.
Va´clavík et al
Spironolactone in Resistant Hypertension
1075
by guest on October 5, 2017
http://hyper.ahajournals.org/
Downloaded from
Václavík, Roman Husár, Eva Kociánová and Milos Táborský
Jan Václavík, Richard Sedlák, Martin Plachý, Karel Navrátil, Jirí Plásek, Jirí Jarkovský, Tomás
(ASPIRANT): A Randomized, Double-Blind, Placebo-Controlled Trial
Addition of Spironolactone in Patients With Resistant Arterial Hypertension
Print ISSN: 0194-911X. Online ISSN: 1524-4563
Copyright © 2011 American Heart Association, Inc. All rights reserved.
is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Hypertension
doi: 10.1161/HYPERTENSIONAHA.111.169961
2011;57:1069-1075; originally published online May 2, 2011;
Hypertension.
http://hyper.ahajournals.org/content/57/6/1069
World Wide Web at:
The online version of this article, along with updated information and services, is located on the
/content/65/2/e7.full.pdf
An erratum has been published regarding this article. Please see the attached page for:
http://hyper.ahajournals.org/content/suppl/2011/04/29/HYPERTENSIONAHA.111.169961.DC1
Data Supplement (unedited) at:
http://hyper.ahajournals.org//subscriptions/
is online at:
Hypertension
Information about subscribing to
Subscriptions:
http://www.lww.com/reprints
Information about reprints can be found online at:
Reprints:
document.
Permissions and Rights Question and Answer
this process is available in the
click Request Permissions in the middle column of the Web page under Services. Further information about
Office. Once the online version of the published article for which permission is being requested is located,
can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial
Hypertension
in
Requests for permissions to reproduce figures, tables, or portions of articles originally published
Permissions:
by guest on October 5, 2017
http://hyper.ahajournals.org/
Downloaded from
e7
In the article by Václavík et al (Václavík J, Sedlák R, Plachý M, Navrátil K, Plášek J, Jarkovský
J, Václavík T, Husár R, Kociánová E, Táborský M. Addition of Spironolactone in Patients With
Resistant Arterial Hypertension (ASPIRANT): A Randomized, Double-Blind, Placebo-Controlled
Trial. Hypertension. 2011;57:1069–1075), which published online May 2, 2011, and appeared in
the June 2011 issue of the journal, corrections were needed.
1. On page 1069, in the abstract, lines 10–11 read “(difference of −8.6, −9.8, and −6.5 mm Hg;
P
=0.011, 0.004, and 0.011)” and has been changed to read “(difference of −8.6, −6.6, and
−6.5 mm Hg; P=0=0.011, 0.004, and 0.011).”
2. On page 1073, in Table 2, the 24-h ambulatory blood pressure monitoring (ABPM) systolic
BP for Spironolactone read “−13.8 (±11.8)” and has been changed to read “−10.6 (±11.8).”
The 24-h ABPM systolic BP Between-Group Difference read “−9.8 (−14.4; −5.2)” and has
been changed to read “−6.6 (−11.2; −2.0).”
The authors apologize for these errors.
These corrections have been made to the current online version of the article, which is available
at http://hyper.ahajournals.org/content/57/6/1069.full.
Correction
(Hypertension. 2015;65:e7. DOI: 10.1161/HYP.0000000000000019.)
© 2014 American Heart Association, Inc.
Hypertension is available at http://hyper.ahajournals.org
DOI: 10.1161/HYP.0000000000000019
ONLINE SUPPLEMENT
ADDITION OF SPIRONOLACTONE IN PATIENTS WITH RESISTANT ARTERIAL
HYPERTENSION (ASPIRANT): A RANDOMIZED, DOUBLE-BLIND, PLACEBO-
CONTROLLED TRIAL
Short title: SPIRONOLACTONE IN RESISTANT HYPERTENSION
1
Jan Václavík, MD., Ph.D.,
2
Richard Sedlák, MD.,
3
Martin Plachý, MD.,
4
Karel Navrátil,
MD.,
5
Ji
ří Plášek, MD.,
6
Jiří Jarkovský, RNDr., Ph.D.,
7
Tomáš Václavík, Mgr.,
8
Roman
Husár, MD.,
1
Eva Kociánová, MD.,
1
Miloš Táborský, MD., Ph.D., ass. Prof.
1
Department of Internal Medicine I, University Hospital Olomouc and Palacký University
School of Medicine, Olomouc,
Czech Republic;
2
Department of Internal Medicine, Prostějov
Hospital, Prostějov, Czech Republic;
3
Internal Medicine Department II,
St. Anne's University
Hospital, Brno, Czech Republic;
4
Department of Internal Medicine, Military Hospital,
Olomouc, Czech Republic;
5
Department of Internal Medicine, University Hospital Ostrava,
Ostrava, Czech Republic;
6
Institute of Biostatistics and Analyses at the Faculty of Medicine
and the Faculty of Science of the Masaryk
University, Brno, Czech Republic;
7
Statistics and
Probability Department, Faculty of Informatics and Statistics, University of Economics in
Prague, Prague, Czech Republic;
8
Department of Internal Medicine, Hranice Hospital,
Hranice na Moravě, Czech Republic
Correspondence to: Jan Václavík, MD., Ph.D., Department of Internal Medicine I, University
Hospital Olomouc, I.P. Pavlova 6, 775 20 Olomouc, Czech Republic
E-mail: vaclavik.j@centrum.cz, Phone: +420-588443209, Fax: +420-588442500
Table S1: Change of diastolic BP at 8 weeks compared to baseline according to diastolic
BP at entry.
Baseline diastolic BP
Spironolactone
(n=55)
Placebo
(n=56)
Between group
difference
*
p
†
Office diastolic BP (mm Hg)
‡
≤90 mm Hg at entry (N=20 / N=25)
-3.6 (±8.4)
-1.6 (±6.3)
-2.0 (-4.8; 0.8)
0.234
>90 mm Hg at entry (N=35 / N=31)
-8.3 (±9.9)
-6.1 (±9.7)
-2.2 (-5.8; 1.4)
0.269
ABPM day-time diastolic BP (mm Hg)
≤85 mm Hg at entry (N=32 / N=36)
-2.5 (±7.1)
-0.8 (±6.2)
-1.7 (-4.2; 0.8)
0.171
>85 mm Hg at entry (N=23 / N=20)
-6.5 (±8.8)
-7.4 (±9.8)
0.9 (-2.6; 4.4)
0.679
Data are mean (SD) when normally distributed
*
Difference between
spironolactine and placebo group is expressed as difference in their
means supplemented by 95% confidence interval
†
Statistical significance was tested by Mann-Whitney U test.
‡
Average of 2
nd
and 3
rd
office BP measurements.
Table S2: Adverse events in the trial
Adverse events
Spironolactone
(n=55)
Placebo
(n=56)
p
Total
24
26
0.849
Severe adverse event,
leading to treatment
discontinuation
2
1
0.618
(1 patient acute gastroenteritis with
symptomatic hypotension <100/50, 1
patient diarrhoea and dyspepsia)
(1 acute urinary colic)
Adverse events –
relation to study
medication unlikely
7
7
0.999
(2
noncardiac chest pain, 1
emotional distraction, 1 skin itching,
1 rise of BP, 1 migraine, 1 facial
flushing after treatment initiation)
(2 dry cough, 1 rectal bleeding, 1
hand paresthesia, 1 hand and feet
dysesthesia, 1 flushes and bad
sleep, 1 fluctuations of glycemia)
Adverse events –
relation to study
medication possible
7
8
0.999
(2 exertional dyspnea, 2 fatigue, 1
tinnitus, 1 scruff pain, 1 transitory
discomfort in the right subcostal
region)
(3 exertional dyspnea, 4
headache, 1 transient dyspepsia
and pacemaker implantation
because of AV block)
Adverse events –
relation to study
medication probable
8
10
0.798
(5 vertigo, 1 gouty attack, 1
transitory diarrhoea, 1 decreased
potency)
(8 vertigo, 2 weakness)